Key result
Influenza vaccination was associated with a reduction in myocardial infarctions (RR 0.84; 95% CI 0.82-0.87; P<0.001) and overall mortality (RR 0.38; 95% CI 0.36-0.40; P<0.001).
Why the study?
Influenza imparts a significant health burden and is associated with acute cardiovascular events, prompting a review of the role of seasonal influenza vaccination in mitigating cardiovascular risk.
Does seasonal influenza vaccination reduce cardiovascular events and mortality?
Does seasonal influenza vaccination reduce cardiovascular events and mortality?
Relative Risk: 0.84 (95% CI 0.82–0.87)
p-value: p=< 0.001
Seasonal influenza vaccination is associated with a significant reduction in cardiovascular events and overall mortality, highlighting its importance in cardiovascular risk mitigation.
May support vaccination in CV risk reduction; leaves open causality and need for RCTs.
PURPOSE OF REVIEW: Influenza imparts a significant health burden on the United States and global population. Furthermore, influenza is associated with acute cardiovascular events, including heart failure exacerbations, acute coronary syndromes, strokes, and overall cardiovascular mortality. We review the role of seasonal influenza vaccination in mitigating cardiovascular risk. RECENT FINDINGS: A large study assessed the impact of influenza vaccine on cardiovascular outcomes and mortality using the US National Inpatient Sample (NIS) database. This study included 22 634 643 hospitalizations. Vaccination against influenza was associated with a reduction in myocardial infarctions (MI) [relative risk (RR) = 0.84, 95% CI 0.82-0.87, P < 0.001], transient ischemic attacks (RR = 0.93, 95% CI 0.9-0.96, P < 0.001), cardiac arrests (RR = 0.36, 95% CI 0.33-0.39, P < 0.001), strokes (RR = 0.94, 95% CI 0.91-0.97, P < 0.001), and overall mortality (RR = 0.38, 95% CI 0.36-0.4, P < 0.001). SUMMARY: Available data suggests that seasonal influenza vaccination is very effective in mitigating cardiovascular risk. Increasing the rates of influenza vaccination, especially among those with cardiovascular risk factors, is critical in preventing infection and attenuating influenza-related cardiovascular complications and adverse outcomes.
No takes yet. Share an insight, caveat, or question.
Mares et al. (2022) conducted a review in cardiovascular risk (n=22,634,643). Influenza vaccination was evaluated on myocardial infarctions (MI) (RR 0.84, 95% CI 0.82-0.87, p=< 0.001). Influenza vaccination was associated with a reduction in myocardial infarctions (RR 0.84; 95% CI 0.82-0.87; P<0.001) and overall mortality (RR 0.38; 95% CI 0.36-0.40; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: